Why Germany is falling behind in Cell and Gene Therapeutics (CGT) and how we can turn it around
In recent years, Germany’s role in biotech has evolved, particularly in cell and gene therapy manufacturing, where its strong GMP expertise is both an asset and a challenge. While Germany remains a key hub for innovation, complex bureaucracy, extensive documentation requirements, and rigid GMP standards have made scaling advanced therapies slow and costly.